NCT05083169 2026-03-18
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
88 trialsNCT04133636 2026-03-17
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04181827 2026-03-16
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03901963 2026-03-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108195 2026-03-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04722146 2026-03-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06425991 2026-03-13
MajesTEC-10
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06577025 2026-03-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT03984097 2026-03-10
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Active not recruiting
NCT03844048 2026-03-06
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
NCT03741127 2026-03-04
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05090566 2026-02-23
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Active not recruiting
NCT05587972 2026-02-23
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems, Inc.
Phase NA Active not recruiting
NCT05955508 2026-02-23
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT05646836 2026-02-17
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Active not recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT04162210 2026-02-11
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT05396885 2026-02-11
iMMagine-1
Gilead Sciences
Phase 2 Active not recruiting
NCT05535244 2026-02-09
CAMMA 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03933735 2026-02-06
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1/2 Active not recruiting
NCT05742217 2026-02-02
MUST
Pfizer
Active not recruiting
NCT03652064 2026-01-20
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04586426 2026-01-16
RedirecTT-1
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05455320 2026-01-16
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03246529 2026-01-15
GENESIS
BioLineRx, Ltd.
Phase 3 Active not recruiting
NCT05954780 2026-01-14
SEATTLE
iOMEDICO AG
Active not recruiting
NCT05013190 2026-01-08
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
Takeda
Active not recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04557150 2025-12-26
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
Hoffmann-La Roche
Phase 1 Active not recruiting
NCT04910568 2025-12-24
CAMMA 1
Genentech, Inc.
Phase 1 Active not recruiting
NCT05317416 2025-12-22
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
NCT05259839 2025-12-19
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1 Active not recruiting
NCT04270409 2025-12-12
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
Phase 3 Active not recruiting
NCT04184050 2025-12-05
MK-4002-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting
NCT01838512 2025-12-02
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Bristol-Myers Squibb
Active not recruiting
NCT04649359 2025-12-02
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Phase 2 Active not recruiting
NCT04091126 2025-11-28
DREAMM 9
GlaxoSmithKline
Phase 1 Active not recruiting
NCT03106324 2025-11-24
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
Active not recruiting
NCT06581848 2025-11-24
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
Pfizer
Active not recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT07217119 2025-10-15
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05064358 2025-10-07
DREAMM 14
GlaxoSmithKline
Phase 2 Active not recruiting
NCT06479954 2025-10-02
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Pfizer
Active not recruiting